NASDAQ:NVCR NovoCure (NVCR) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free NVCR Stock Alerts $15.53 -0.02 (-0.13%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$15.31▼$16.2550-Day Range$11.83▼$17.2952-Week Range$10.87▼$83.60Volume904,367 shsAverage Volume1.33 million shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$30.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get NovoCure alerts: Email Address NovoCure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside98.8% Upside$30.88 Price TargetShort InterestBearish6.27% of Float Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment0.06Based on 18 Articles This WeekInsider TradingSelling Shares$127,161 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.78) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector146th out of 903 stocksSurgical & Medical Instruments Industry22nd out of 95 stocks 4.3 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageNovoCure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NovoCure's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.27% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in NovoCure has recently increased by 20.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 2.3 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for NovoCure this week, compared to 5 articles on an average week.Search Interest9 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,161.00 in company stock.Percentage Held by InsidersOnly 5.67% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NovoCure's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.78) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NovoCure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About NovoCure Stock (NASDAQ:NVCR)NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Read More NVCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Stock News HeadlinesMay 6, 2024 | americanbankingnews.comWedbush Reiterates "Neutral" Rating for NovoCure (NASDAQ:NVCR)May 4, 2024 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Price Target Cut to $22.00May 8, 2024 | Paradigm Press (Ad)AI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.May 3, 2024 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | seekingalpha.comNovoCure Limited Q1 Earnings: Core Business AcceleratingMay 3, 2024 | fool.comNovoCure (NVCR) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comUnveiling 8 Analyst Insights On NovoCureMay 2, 2024 | investorplace.comNVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | Paradigm Press (Ad)AI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.May 2, 2024 | finance.yahoo.comNovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss ReportedMay 2, 2024 | seekingalpha.comNovoCure Limited 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | businesswire.comNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from PharmakonMay 2, 2024 | businesswire.comNovocure Reports First Quarter 2024 Financial ResultsMay 1, 2024 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Sees Significant Growth in Short InterestApril 30, 2024 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by AnalystsApril 24, 2024 | finance.yahoo.comResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024April 24, 2024 | businesswire.comResults of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024April 11, 2024 | markets.businessinsider.comBuy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial ExecutionApril 5, 2024 | businesswire.comNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024April 3, 2024 | markets.businessinsider.comNovoCure (NVCR) Receives a Buy from Wells FargoApril 1, 2024 | finance.yahoo.comNovocure to Report First Quarter 2024 Financial ResultsMarch 30, 2024 | fool.comWhy NovoCure Stock Soared 18.3% This WeekMarch 29, 2024 | markets.businessinsider.comNovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price TargetMarch 28, 2024 | fool.comWhy Novocure Stock Is Jumping TodayMarch 27, 2024 | seekingalpha.comNovoCure: Sell The METIS-Inspired RallyMarch 27, 2024 | markets.businessinsider.comNuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s StockMarch 27, 2024 | msn.comNovocure's device shown to slow cancer progression in the brain in trialSee More Headlines Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/08/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,453Year FoundedN/APrice Target and Rating Average Stock Price Target$30.88 High Stock Price Target$51.00 Low Stock Price Target$15.00 Potential Upside/Downside+98.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-207,040,000.00 Net Margins-36.67% Pretax Margin-32.78% Return on Equity-50.35% Return on Assets-16.86% Debt Debt-to-Equity Ratio1.59 Current Ratio6.26 Quick Ratio5.99 Sales & Book Value Annual Sales$509.34 million Price / Sales3.28 Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book4.58Miscellaneous Outstanding Shares107,610,000Free Float101,509,000Market Cap$1.67 billion OptionableOptionable Beta0.50 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. William F. Doyle (Age 62)Executive Chairman Comp: $1.52MMr. Asaf Danziger (Age 58)CEO & Director Comp: $1.7MMs. Ashley Cordova (Age 45)Chief Financial Officer Comp: $933.39kMr. Wilhelmus C. M. Groenhuysen (Age 66)Chief Operating Officer Comp: $1.01MMr. Frank LeonardExecutive VP & President of Novocure OncologyProf. Yoram Palti M.D. (Age 86)Ph.D., Founder & CTO Comp: $282.51kDr. Moshe Giladi Ph.D. (Age 54)Chief Science Officer Ms. Ingrid GoldbergVP of Investor RelationsMr. Barak Ben Arye (Age 47)General Counsel Mr. Michael Puri (Age 55)Chief Human Resources Officer More ExecutivesKey CompetitorsLeMaitre VascularNASDAQ:LMATAlphatecNASDAQ:ATECIntegra LifeSciencesNASDAQ:IARTMiMedx GroupNASDAQ:MDXGAtriCureNASDAQ:ATRCView All CompetitorsInsiders & InstitutionsHeadlands Technologies LLCBought 8,589 shares on 5/8/2024Ownership: 0.008%SG Americas Securities LLCBought 130,927 shares on 5/7/2024Ownership: 0.334%Quantbot Technologies LPBought 16,681 shares on 5/6/2024Ownership: 0.060%Daiwa Securities Group Inc.Bought 4,700 shares on 5/2/2024Ownership: 0.005%BNP Paribas Financial MarketsSold 112,385 shares on 5/1/2024Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions NVCR Stock Analysis - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVCR shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price target for 2024? 9 brokerages have issued 1-year price targets for NovoCure's stock. Their NVCR share price targets range from $15.00 to $51.00. On average, they anticipate the company's share price to reach $30.88 in the next year. This suggests a possible upside of 98.8% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2024? NovoCure's stock was trading at $14.93 at the start of the year. Since then, NVCR shares have increased by 4.0% and is now trading at $15.53. View the best growth stocks for 2024 here. Are investors shorting NovoCure? NovoCure saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 6,040,000 shares, an increase of 20.6% from the March 31st total of 5,010,000 shares. Based on an average daily volume of 1,270,000 shares, the days-to-cover ratio is presently 4.8 days. Currently, 6.3% of the shares of the company are short sold. View NovoCure's Short Interest. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our NVCR earnings forecast. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, May, 2nd. The medical equipment provider reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The medical equipment provider had revenue of $138.50 million for the quarter, compared to analyst estimates of $131.44 million. NovoCure had a negative net margin of 36.67% and a negative trailing twelve-month return on equity of 50.35%. The firm's quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.50) EPS. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include Counterpoint Quantitative Equity ETF (CPAI) and Amplify BlueStar Israel Technology ETF (ITEQ).iShares U.S. Medical Devices ETF (IHI). What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). Who are NovoCure's major shareholders? NovoCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (1.85%), SG Americas Securities LLC (0.33%), Taylor Frigon Capital Management LLC (0.12%), SpiderRock Advisors LLC (0.08%), Quantbot Technologies LP (0.06%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVCR) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
